CG Oncology aims for $209M IPO, as more biotechs eye path to public markets

Investment firm Mirae launches its US biotech VC fund with $50M

Return of the SPAC? Bihua Chen and Cormorant go for round two after MoonLake success

Novartis axes PhIII peanut allergy trial in another blow for once-hopeful Xolair successor

BridgeBio raises up to $1.2B, a month after submitting cardio drug to FDA

Bristol Myers Squibb has targeted launch plan for ‘multi-billion-dollar opportunity’ in Karuna schizophrenia drug

AEON Biopharma: Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors

Novo Holdings plans to ramp up dealmaking amid Wegovy windfall: Bloomberg

JPM24: Roche’s pharma BD chief explains renewed ADC interest but is spoilt for choice

Novartis reportedly backs out of Cytokinetics deal, denting biotech’s stock

J&J wins full approval for bladder cancer drug

Illumina Ventures launches refreshed genomics startup accelerator program

Exclusive: Two biotechs merge to form Calluna, with €75M in hand to focus on immunotherapy antibodies

ArriVent outlines plans for $135M IPO in second biotech listing of 2024

Coherus sells Sandoz its Lucentis biosimilar for $170M to focus on oncology assets

Former Theranos CEO Elizabeth Holmes is banned from federal health programs for almost a century

AstraZeneca, Boehringer Ingelheim, GSK defend patent listings as Klobuchar amps up pressure